Lv41
770 积分 2025-07-27 加入
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
1小时前
已完结
Trastuzumab pamirtecan (DB-1303/BNT323) in patients with previously treated HER2-expressing advanced/metastatic endometrial cancer: First global clinical phase 2 data
3天前
已关闭
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
3天前
已完结
Advances in RAS Therapeutics for Pancreatic Cancer
10天前
已完结
The evolving landscape of obesity pharmacotherapy
19天前
已完结
Natriuretic Peptide Receptor-1 Agonist for Resistant Hypertension
1个月前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
1个月前
已完结
Prime Editing for p47 phox -Deficient Chronic Granulomatous Disease
1个月前
已完结
Celiac Disease
1个月前
已完结
Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase (AKR1C3)
1个月前
已完结
皖公网安备34019202002308
